iMetabolic Biopharma

Executive Summary

iMetabolic Biopharma (iMBP) is an early-stage precision medicine company based in San Diego, developing therapeutics for obesity-related comorbidities, with a focus on cardiovascular disease. The company leverages a proprietary TechBio AI platform to accelerate drug discovery and development. Founded in 2018, iMBP operates in the biologics category and is privately held. As of early 2026, the company has not disclosed any pipeline candidates or financing rounds, indicating it is likely in preclinical or platform-validation stages. The AI-driven approach positions iMBP to address the growing obesity epidemic and its cardiovascular consequences, a large unmet medical need. However, the lack of publicly available data on specific programs or funding raises uncertainty about progress and timelines. The company's success hinges on advancing its platform toward lead identification and securing partnerships or funding to support preclinical development.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement60% success
• Q1 2027Lead Candidate Nomination for Obesity-CVD Program40% success
• Q3 2026Publication or Proof-of-Concept Data for AI Platform50% success